https://pipelinereview.com/keytruda-pembrolizumab-demonstrated-improved-health-related-quality-of-life-compared-to-chemotherapy-in-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc/
KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)